Intelligence · Clinical Pipeline
Kailera Therapeutics Pipeline
All ClinicalTrials.gov programs at Kailera Therapeutics — phase, modality, and trial IDs.
- Programs
- 17
Quick answer
Kailera Therapeutics has 17 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
-
GC4419 90mg
Galera Therapeutics
Oral Mucositis
1 trial -
Drug GC4711
Galera Therapeutics
SBRT
1 trial -
Drug: GC4419
Galera Therapeutics
Head and Neck Cancer
1 trial -
GC4419
Galera Therapeutics
Pancreatic Cancer
1 trial -
GC4419
Galera Therapeutics
Covid19
1 trial -
GC4419 (avasopasem manganese)
Galera Therapeutics
Esophagitis
1 trial -
GC4711 +SBRT
Galera Therapeutics
SBRT
1 trial -
Low Dose GC4419: 30mg/day
Galera Therapeutics
Radiation Induced Oral Mucositis
1 trial -
Dextromethorphan HBr
Galera Therapeutics
Healthy
1 trial -
GC4419
Galera Therapeutics
Healthy Volunteers
1 trial -
GC4419
Galera Therapeutics
Renal Impairment
1 trial -
GC4419
Galera Therapeutics
Squamous Cell Carcinoma of the Oral Cavity
1 trial -
GC4419 IV
Galera Therapeutics
Healthy Volunteers
1 trial -
GC4702 dry powder
Galera Therapeutics
Healthy Volunteer
1 trial -
GC4711 30 mg IV
Galera Therapeutics
Healthy Volunteers
1 trial -
GC4711 30mg
Galera Therapeutics
Healthy
1 trial -
GC4711 Oral Capsule G-101
Galera Therapeutics
Healthy Volunteers
1 trial
Frequently asked questions
How many pipeline programs does Kailera Therapeutics have?
17 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.
Data attribution: Data sources · All pipeline programs